Key Highlights

  • Tyra Biosciences shares closed up 14% at $25.07.
  • The company priced a $400 million underwritten public offering of common stock and pre-funded warrants.
  • The offering was priced at $22.03 per share equivalent, spearheaded by RA Capital.
  • Proceeds will fund the dabogratinib 3x3 pipeline across LG-UTUC, IR NMIBC, and achondroplasia indications.

Tyra Biosciences, Inc. (NASDAQ: TYRA) shares closed up 14% at $25.07 after the company announced the pricing of a $400 million underwritten public offering featuring common stock alongside pre-funded warrants at $22.03 per share equivalent, spearheaded by RA Capital alongside broad institutional backing.

What Happened

The company aims to allocate the capital toward progressing its dabogratinib 3x3 pipeline across LG-UTUC, IR NMIBC, and achondroplasia indications while funding preclinical research and general operational needs.

Market Reaction

Shares rose despite the sizable offering, suggesting investors viewed the substantial new capital as supportive of Tyra's broadened multi-indication pipeline strategy for dabogratinib.

Outlook

Continued clinical progress across the dabogratinib 3x3 pipeline in LG-UTUC, IR NMIBC, and achondroplasia, now backed by the $400 million raise, represents the next relevant development for Tyra Biosciences.